Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Scheinberg

Showing results (61-70 of 121) with videos related to

Pageof 13
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 1999
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical useM R McDevitt, R D Finn, D Ma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1993
Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemiaG Sgouros, M C Graham, C R Divgi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemiaS E Kossman, D A Scheinberg, J G Jurcic, et al.
Leukemia|June 1, 1989
Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemiaD A Scheinberg, M Tanimoto, S McKenzie, et al.
Cell Death & Disease|March 29, 2014
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancersA Sheth, S Escobar-Alvarez, J Gardner, et al.
Blood|March 15, 1993
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemiaP Maslak, W H Miller, G Heller, et al.
Tissue Antigens|November 1, 1991
Inhibition of cell proliferation with an HLA-A-specific monoclonal antibodyD A Scheinberg, M K Bull, S Y Yang, et al.
Leukemia|May 1, 1989
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195M Tanimoto, D A Scheinberg, C Cordon-Cardo, et al.
Blood|May 1, 1996
Specific human cellular immunity to bcr-abl oncogene-derived peptidesM Bocchia, T Korontsvit, Q Xu, et al.
The Journal of Experimental Medicine|October 1, 1992
Engineered humanized dimeric forms of IgG are more effective antibodiesP C Caron, W Laird, M S Co, et al.
Pageof 13

Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 1999
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical useM R McDevitt, R D Finn, D Ma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1993
Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemiaG Sgouros, M C Graham, C R Divgi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemiaS E Kossman, D A Scheinberg, J G Jurcic, et al.
Leukemia|June 1, 1989
Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemiaD A Scheinberg, M Tanimoto, S McKenzie, et al.
Cell Death & Disease|March 29, 2014
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancersA Sheth, S Escobar-Alvarez, J Gardner, et al.
Blood|March 15, 1993
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemiaP Maslak, W H Miller, G Heller, et al.
Tissue Antigens|November 1, 1991
Inhibition of cell proliferation with an HLA-A-specific monoclonal antibodyD A Scheinberg, M K Bull, S Y Yang, et al.
Leukemia|May 1, 1989
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195M Tanimoto, D A Scheinberg, C Cordon-Cardo, et al.
Blood|May 1, 1996
Specific human cellular immunity to bcr-abl oncogene-derived peptidesM Bocchia, T Korontsvit, Q Xu, et al.
The Journal of Experimental Medicine|October 1, 1992
Engineered humanized dimeric forms of IgG are more effective antibodiesP C Caron, W Laird, M S Co, et al.
Pageof 13